1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
Opportunity Analyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024

Opportunity Analyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024

  • June 2015
  • 153 pages
  • ID: 3267660
In this report:
GLOBALDATA ESTIMATES THAT THE MYASTHENIA GRAVIS MARKET SALES IN 2014 ACROSS THE ##EU WERE APPROXIMATELY $##M AND ARE EXPECTED TO INCREASE TO $##M BY 2024, REPRESENTING AN AVERAGE CAGR OF ##.##%.
GLOBALDATA ESTIMATES THAT THE 2014 BASE-YEAR MARKET SALES IN JAPAN WERE APPROXIMATELY $##M AND ARE EXPECTED TO INCREASE TO $##M BY 2024, WHICH REPRESENTS A CAGR OF ##.##%.

Summary

Table of Contents

Search Inside

Opportunity Analyzer: Myasthenia Gravis - Opportunity Analysis and Forecasts to 2024

Brief

Myasthenia gravis is an autoimmune disease affecting the nervous system. While myasthenia gravis is a rare disease, it is considered to be the most common neuromuscular disorder and presents itself as a weakness of the muscles. In the majority of patients the disease is initially localized and limited to the eye muscles causing a drooping of the eyelid and double vision. The majority of patients progress to a more severe and generalized form, where the disease spreads to other muscles including bulbar, limb, and respiratory muscles. Weakness of the respiratory muscles can lead to shortness of breath or in more severe cases it can lead to the patients requiring assisted ventilation. A worsening of myasthenia gravis of this sort is referred to as myasthenia crisis and is a life threatening condition, which typically occurs within the first two years after myasthenia gravis onset.

Key Findings

Key questions & answers

- The myasthenia gravis market has been dominated by short and long-term-immunosuporessants and acetylcholinesterase inhibitors in the final decades. New classes of drugs are anticipated the reach the market within the forecast period. How will these drugs change the myasthenia gravis market? What impact will they have on the market value?

- The current late stage myasthenia gravis pipeline is dominated by monoclonal antibodies. Which monoclonal antibody will have the biggest impact on the industry? What strategies are developers undertaking to penetrate this highly generic market? Will the additional drugs fulfil any unmet needs?

- Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is anticipated to have a meaningful impact on the prevalence of myasthenia gravis. How will epidemiological changes impact the growth of the future market?

Main highlights

- The principal driver of growth in the myasthenia gravis market will be the introduction of monoclonal antibodies over the forecast period. The increase in prevalence will support the market increase and a high level of unmet needs will insure that the sector remains interesting in the future.

- The biggest barrier for increase in the myasthenia gravis market are anticipated difficulties for the reimbursement of monoclonal antibodies. Furthermore, the myasthenia gravis market is dominated by generics and off-label drugs, limiting treatment cost for patients who have an acceptable level of disease control.

- The biggest unmet needs in myasthenia gravis is a targeted, steroid sparing therapy. Approximately 10.0 percent of patients are currently treatment refractory and urgently need additional treatment options. Patients currently treated with steroids also would benefit from treatment regimen additions.

Overview

- Overview of myasthenia gravis, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

- Annualized myasthenia gravis a market revenue, annual cost of therapy and treatment usage pattern data from 2014 and estimate for ten years to 2024.

- Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the myastenia gravis therapeutics market.

- Pipeline analysis: focus on the late-stage pipeline myasthenia gravis drugs discussing emerging trends as well as overview of earlier phase drugs.

- Analysis of the current and future market competition in the overall myasthenia gravisa therapeutics market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline.

- Additionally a list of acquisition targets included in the pipeline product company list.

- Develop strategic management by understanding the trends shaping and driving the overall myasthenia gravis therapeutics market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall myasthenia gravis therapeutics market in future.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analysing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Track drug sales in the overall myasthenia gravis therapeutics market from 2014-2024.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Amrita helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Lambert-Eaton Myasthenic Syndrome (LEMS) Global Clinical Trials Review, H2, 2017

Clinical Research in Lambert-Eaton Myasthenic Syndrome (LEMS) in H2, 2017

  • $ 2500
  • Industry report
  • November 2017
  • by GlobalData

Lambert-Eaton Myasthenic Syndrome (LEMS) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, "Lambert-Eaton Myasthenic Syndrome (LEMS) Global Clinical Trials Review, H2, ...

Infantile Spasm (West Syndrome) Global Clinical Trials Review, H2, 2017

Clinical Research in Infantile Spasm (West Syndrome) in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Infantile Spasm (West Syndrome) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Infantile Spasm (West Syndrome) Global Clinical Trials Review, H2, 2017" provides ...

Hypersomnia Global Clinical Trials Review, H2, 2017

Clinical Research in Hypersomnia in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Hypersomnia Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hypersomnia Global Clinical Trials Review, H2, 2017" provides an overview of Hypersomnia clinical trials ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.